Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIRIUS-SLE 1 phase 3 study of ianalumab added to standard care in systemic lupus erythematosus
MOH_2023-06-06_012622Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- May 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ianalumab in systemic lupus erythematosus (SLE) (3 arms), sponsored by Novartis. Started May 2023; status: active, not recruiting.
02
Drugs
ianalumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on MOH_2023-06-06_012622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-06-06_012622.